Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | REPL |
---|---|---|
09:32 ET | 4765 | 12.27 |
09:34 ET | 1365 | 12.35 |
09:36 ET | 1678 | 12.48 |
09:38 ET | 3209 | 12.64 |
09:39 ET | 3805 | 12.5 |
09:41 ET | 1000 | 12.475 |
09:43 ET | 2100 | 12.415 |
09:45 ET | 1917 | 12.35 |
09:48 ET | 1505 | 12.44 |
09:50 ET | 4694 | 12.45 |
09:52 ET | 2200 | 12.47 |
09:54 ET | 2737 | 12.48 |
09:56 ET | 2863 | 12.495 |
09:57 ET | 3888 | 12.455 |
09:59 ET | 6682 | 12.38 |
10:01 ET | 1022 | 12.39 |
10:03 ET | 1459 | 12.355 |
10:06 ET | 200 | 12.43 |
10:08 ET | 1655 | 12.505 |
10:10 ET | 2970 | 12.43 |
10:12 ET | 700 | 12.39 |
10:14 ET | 1005 | 12.38 |
10:15 ET | 2643 | 12.31 |
10:17 ET | 1574 | 12.25 |
10:19 ET | 1058 | 12.19 |
10:21 ET | 550 | 12.19 |
10:24 ET | 550 | 12.18 |
10:26 ET | 500 | 12.1377 |
10:28 ET | 8877 | 12.1 |
10:30 ET | 700 | 12.11 |
10:32 ET | 400 | 12.08 |
10:33 ET | 300 | 12.12 |
10:35 ET | 100 | 12.13 |
10:37 ET | 2500 | 12.27 |
10:39 ET | 500 | 12.26 |
10:42 ET | 600 | 12.26 |
10:44 ET | 3794 | 12.225 |
10:46 ET | 1200 | 12.25 |
10:48 ET | 500 | 12.27 |
10:50 ET | 200 | 12.3 |
10:51 ET | 1800 | 12.31 |
10:53 ET | 2350 | 12.26 |
10:55 ET | 2942 | 12.19 |
10:57 ET | 1969 | 12.185 |
11:00 ET | 300 | 12.18 |
11:02 ET | 2100 | 12.13 |
11:04 ET | 708 | 12.16 |
11:06 ET | 1145 | 12.11 |
11:08 ET | 400 | 12.14 |
11:09 ET | 700 | 12.13 |
11:11 ET | 600 | 12.15 |
11:13 ET | 700 | 12.11 |
11:15 ET | 300 | 12.16 |
11:18 ET | 300 | 12.16 |
11:20 ET | 1400 | 12.12 |
11:22 ET | 758 | 12.14 |
11:24 ET | 2835 | 12.22 |
11:26 ET | 2300 | 12.245 |
11:27 ET | 3000 | 12.18 |
11:29 ET | 200 | 12.15 |
11:31 ET | 300 | 12.17 |
11:33 ET | 2553 | 12.2 |
11:36 ET | 670 | 12.19 |
11:38 ET | 905 | 12.18 |
11:40 ET | 600 | 12.15 |
11:42 ET | 800 | 12.15 |
11:44 ET | 2268 | 12.18 |
11:45 ET | 800 | 12.14 |
11:47 ET | 1814 | 12.18 |
11:49 ET | 700 | 12.2 |
11:51 ET | 1200 | 12.19 |
11:54 ET | 1600 | 12.17 |
11:56 ET | 400 | 12.2 |
11:58 ET | 1900 | 12.17 |
12:00 ET | 1005 | 12.13 |
12:02 ET | 100 | 12.175 |
12:03 ET | 2400 | 12.09 |
12:05 ET | 200 | 12.05 |
12:07 ET | 826 | 12.07 |
12:09 ET | 800 | 12.06 |
12:12 ET | 1555 | 12.03 |
12:14 ET | 300 | 12.035 |
12:16 ET | 2650 | 12.06 |
12:18 ET | 300 | 12.07 |
12:20 ET | 1450 | 12.06 |
12:21 ET | 3700 | 12.11 |
12:25 ET | 972 | 12.18 |
12:27 ET | 400 | 12.15 |
12:30 ET | 3200 | 12.12 |
12:32 ET | 709 | 12.11 |
12:34 ET | 1050 | 12.1 |
12:36 ET | 300 | 12.06 |
12:38 ET | 1183 | 12.01 |
12:39 ET | 1611 | 12.05 |
12:41 ET | 400 | 12.04 |
12:43 ET | 1584 | 12.03 |
12:45 ET | 700 | 12.04 |
12:48 ET | 2586 | 12.02 |
12:50 ET | 100 | 12.01 |
12:52 ET | 1130 | 11.9649 |
12:54 ET | 1000 | 12.01 |
12:56 ET | 700 | 12.02 |
12:57 ET | 1000 | 12.06 |
12:59 ET | 1600 | 12.02 |
01:01 ET | 1700 | 11.91 |
01:03 ET | 403 | 11.93 |
01:06 ET | 200 | 11.93 |
01:08 ET | 400 | 11.93 |
01:10 ET | 1900 | 11.92 |
01:12 ET | 1200 | 11.905 |
01:14 ET | 300 | 11.92 |
01:15 ET | 600 | 11.88 |
01:17 ET | 600 | 11.9 |
01:19 ET | 400 | 11.91 |
01:21 ET | 500 | 11.89 |
01:24 ET | 200 | 11.9 |
01:26 ET | 400 | 11.9 |
01:28 ET | 100 | 11.9 |
01:30 ET | 1082 | 11.83 |
01:32 ET | 750 | 11.8 |
01:33 ET | 507 | 11.82 |
01:35 ET | 400 | 11.85 |
01:37 ET | 500 | 11.835 |
01:39 ET | 2400 | 11.795 |
01:42 ET | 200 | 11.79 |
01:44 ET | 1012 | 11.795 |
01:46 ET | 1000 | 11.8 |
01:48 ET | 300 | 11.8 |
01:50 ET | 5230 | 11.77 |
01:51 ET | 100 | 11.72 |
01:53 ET | 424 | 11.73 |
01:55 ET | 450 | 11.7201 |
01:57 ET | 100 | 11.73 |
02:00 ET | 2141 | 11.8 |
02:02 ET | 795 | 11.8 |
02:04 ET | 977 | 11.77 |
02:06 ET | 100 | 11.8 |
02:08 ET | 500 | 11.79 |
02:09 ET | 400 | 11.8 |
02:11 ET | 300 | 11.8 |
02:13 ET | 418 | 11.77 |
02:15 ET | 500 | 11.75 |
02:18 ET | 2086 | 11.72 |
02:20 ET | 1008 | 11.7 |
02:22 ET | 100 | 11.7 |
02:24 ET | 1022 | 11.65 |
02:26 ET | 400 | 11.66 |
02:27 ET | 1648 | 11.68 |
02:29 ET | 714 | 11.68 |
02:31 ET | 1005 | 11.66 |
02:33 ET | 600 | 11.66 |
02:36 ET | 200 | 11.63 |
02:38 ET | 609 | 11.67 |
02:40 ET | 450 | 11.68 |
02:42 ET | 400 | 11.7 |
02:44 ET | 731 | 11.68 |
02:45 ET | 100 | 11.68 |
02:47 ET | 900 | 11.66 |
02:49 ET | 950 | 11.63 |
02:51 ET | 551 | 11.6245 |
02:54 ET | 600 | 11.64 |
02:56 ET | 600 | 11.6 |
02:58 ET | 758 | 11.63 |
03:00 ET | 600 | 11.6 |
03:02 ET | 300 | 11.6 |
03:03 ET | 2115 | 11.68 |
03:05 ET | 700 | 11.675 |
03:07 ET | 834 | 11.735 |
03:09 ET | 604 | 11.72 |
03:12 ET | 600 | 11.71 |
03:14 ET | 1218 | 11.71 |
03:16 ET | 700 | 11.72 |
03:18 ET | 900 | 11.71 |
03:20 ET | 806 | 11.7 |
03:21 ET | 439 | 11.69 |
03:23 ET | 1000 | 11.65 |
03:25 ET | 400 | 11.68 |
03:27 ET | 16176 | 11.73 |
03:30 ET | 4190 | 11.65 |
03:32 ET | 1075 | 11.665 |
03:34 ET | 800 | 11.685 |
03:36 ET | 500 | 11.72 |
03:38 ET | 1763 | 11.72 |
03:39 ET | 1226 | 11.72 |
03:41 ET | 4542 | 11.74 |
03:43 ET | 2168 | 11.735 |
03:45 ET | 1029 | 11.74 |
03:48 ET | 2800 | 11.79 |
03:50 ET | 2820 | 11.84 |
03:52 ET | 4732 | 11.81 |
03:54 ET | 4662 | 11.72 |
03:56 ET | 6097 | 11.7 |
03:57 ET | 10676 | 11.66 |
03:59 ET | 146543 | 11.69 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Replimune Group Inc | 838.3M | -3.6x | --- |
CARGO Therapeutics Inc | 827.7M | -5.0x | --- |
IGM Biosciences Inc | 854.2M | -4.1x | --- |
Dianthus Therapeutics Inc | 821.3M | -5.0x | --- |
Oruka Therapeutics Inc | 875.0M | -4.2x | --- |
Arrivent Biopharma Inc | 799.0M | -10.4x | --- |
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $838.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 68.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.19 |
EPS | $-3.27 |
Book Value | $6.10 |
P/E Ratio | -3.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.